Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study
Authors:
- Alexis B. CortotACAlexis B. Cortot
- Clarisse Audigier-ValetteCAClarisse Audigier-Valette
- Olivier MolinierOMOlivier Molinier
- Sylvestre Le MoulecSMSylvestre Le Moulec
- Fabrice BarlesiFBFabrice Barlesi
- Gérard ZalcmanGZGérard Zalcman
- Patrick DumontPDPatrick Dumont
- Damien PouesselDPDamien Pouessel
- Claire PouletCPClaire Poulet
- Clara Fontaine-DelaruelleCFClara Fontaine-Delaruelle
- Sandrine HiretSHSandrine Hiret
- Adrien DixmierADAdrien Dixmier
- 1 May 2020
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 131, 27-36
Abstract
No abstract availableKeywords
Funding Information
- Roche
This publication has 21 references indexed in Scilit:
- Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: A retrospective studyLung Cancer, 2013
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trialThe Lancet, 2011
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast CancerJournal of Clinical Oncology, 2011
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast CancerJournal of Clinical Oncology, 2010
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2Journal of Clinical Oncology, 2010
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor EfficacyCancer Research, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006